Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of chronic and congenital dacryocystitis
3.2.1.2 Growing awareness towards advanced ophthalmic treatment options
3.2.1.3 Increasing aging population
3.2.1.4 Availability of advanced diagnostic techniques to timely diagnose dacryocystitis
3.2.2 Industry pitfalls & challenges
3.2.2.1 Presence of stringent regulations
3.2.2.2 High risk of side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Surgery
5.3 Medication
5.3.1 Antibiotics
5.3.2 Other medications
Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Chronic dacryocystitis
6.3 Acute dacryocystitis
6.4 Congenital dacryocystitis
Chapter 7 Market Estimates and Forecast, By Distribution channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Institutional sales
7.3 Retail sales
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AbbVie Inc. (Allergan)
9.2 Alcon Inc.
9.3 Aurolab
9.4 Bausch Health Companies Inc.
9.5 Bayer AG
9.6 BVM Medical Limited
9.7 F. Hoffmann-La Roche Ltd (Genentech, Inc.)
9.8 FCI Ophthalmics
9.9 Gunther Weiss Scientific Glassblowing Co., Inc.
9.10 Heart Medical Europe BV
9.11 Kaneka Corporation
9.12 Merck & Co., Inc.
9.13 Novartis AG
9.14 Pfizer Inc.
9.15 Regeneron Pharmaceuticals Inc.
